Synchron: Restoring Independence Through Thought-Controlled Technology
Synchron, a neurotechnology company founded in 2016 by Dr Tom Oxley, is changing the future of human–machine interaction. Its flagship innovation, the Stentrode™, is a minimally invasive brain–computer interface (BCI) designed to help people with paralysis control digital devices using only their thoughts.
What makes Synchron a standout is its endovascular approach. Instead of open-brain surgery, the device is implanted via the jugular vein and rests within the brain’s blood vessels. It’s a safer, faster alternative that uses procedures already familiar to hospitals worldwide.
Synchron was the first BCI company approved by the FDA to conduct human trials in the U.S., with clinical studies also underway in Australia. Early results show patients with motor neurone disease and spinal injuries regaining the ability to communicate digitally—simply by thinking.
Led by Dr Oxley and a multidisciplinary leadership team including Chief Medical Officer Dr J. Mocco, CTO Riki Banerjee, and CCO Kurt Haggstrom, Synchron is poised to make BCI technology not just a breakthrough—but a lifeline.
At its heart, Synchron isn’t just about merging minds with machines. It’s about restoring freedom, dignity, and digital independence to those who’ve lost them.
Why Synchron Is a Game-Changer
Minimally Invasive Technology
Synchron’s greatest innovation lies in its endovascular approach to brain–computer interfaces. Unlike competitors that require open-brain surgery, Synchron implants its device via the jugular vein. This eliminates the need for drilling into the skull, significantly reducing surgical risk and making the procedure more accessible in typical hospital settings.
Real-World Human Use
Synchron isn’t just in the lab—it’s already in people. Their BCI has been implanted in patients living with paralysis, who are now able to control computers and communicate using only their thoughts. These are not theoretical claims—they’re clinically verified outcomes, representing meaningful change in people’s lives.
First FDA-Approved Trials in the U.S.
Synchron is the first company to receive FDA approval to conduct clinical trials of a permanently implanted BCI. This regulatory milestone sets them apart in a highly competitive and tightly controlled field, signalling both credibility and clinical promise.
Designed for Scalability
Because the Stentrode is delivered using standard neurointervention techniques, Synchron’s solution can be rolled out using existing medical infrastructure. This opens the door for broader adoption and integration into routine care—something invasive surgical competitors may struggle to achieve.
Strong Multidisciplinary Team
Synchron is led by experts in neuroscience, biomedical engineering, regulatory affairs, and commercial strategy. This balanced leadership team, with deep experience in both medical practice and commercial execution, gives the company a strong foundation for long-term impact.
Ethical, Human-Centric Focus
Synchron’s mission isn’t simply to push the boundaries of technology—it’s to restore digital agency to those who’ve lost it. Their focus on helping people with paralysis reconnect with the world gives their innovation a clear, human purpose.
Conclusion
Synchron is redefining what’s possible at the intersection of neuroscience and technology. With a minimally invasive solution that’s already changing lives, the company is not just advancing brain–computer interfaces—it’s making them viable, scalable, and human-focused. By empowering individuals with paralysis to regain digital communication through thought alone, Synchron is restoring more than mobility—it’s restoring independence, dignity, and connection. As clinical trials progress and global adoption grows, Synchron stands at the forefront of a future where mind-driven technology is no longer science fiction, but life-changing reality.